Psychopharmacology in children and adolescents: unmet needs and opportunities

Samuele Cortese; Diane Purper-Ouakil; Alan Apter; Celso Arango; Inmaculada Baeza; Tobias Banaschewski; Jan Buitelaar; Josefina Castro-Fornieles; David Coghill; David Cohen; Christoph U. Correll; Edna Grünblatt; Pieter J. Hoekstra; Anthony James; Pia Jeppesen; Péter Nagy; Anne Katrine Pagsberg; Mara Parellada; Antonio M. Persico; Veit Roessner; Paramala Santosh; Emily Simonoff; Dejan Stevanovic; Argyris Stringaris; Benedetto Vitiello; Susanne Walitza; Abraham Weizman; Ian C.K. Wong; Gil Zalsman; Alessandro Zuddas; Sara Carucci; Florence Butlen-Ducuing; Maria Tome; Myriam Bea; Christine Getin; Nina Hovén; Asa Konradsson-Geuken; Daphne Lamirell; Nigel Olisa; Begonya Nafria Escalera; Carmen Moreno

doi:10.1016/S2215-0366(23)00345-0

Psychopharmacology in children and adolescents: unmet needs and opportunities

Samuele Cortese, Diane Purper-Ouakil, Alan Apter, Celso Arango, Inmaculada Baeza, Tobias Banaschewski, Jan Buitelaar, Josefina Castro-Fornieles, David Coghill, David Cohen, Christoph U. Correll, Edna Grünblatt, Pieter J. Hoekstra, Anthony James, Pia Jeppesen, Péter Nagy, Anne Katrine Pagsberg, Mara Parellada, Antonio M. Persico, Veit RoessnerParamala Santosh, Emily Simonoff, Dejan Stevanovic, Argyris Stringaris, Benedetto Vitiello, Susanne Walitza, Abraham Weizman, Ian C.K. Wong, Gil Zalsman, Alessandro Zuddas, Sara Carucci, Florence Butlen-Ducuing, Maria Tome, Myriam Bea, Christine Getin, Nina Hovén, Asa Konradsson-Geuken, Daphne Lamirell, Nigel Olisa, Begonya Nafria Escalera, Carmen Moreno

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Psychopharmacological treatment is an important component of the multimodal intervention approach to treating mental health conditions in children and adolescents. Currently, there are many unmet needs but also opportunities, alongside possible risks to consider, regarding the pharmacological treatment of mental health conditions in children and adolescents. In this Position Paper, we highlight and address these unmet needs and opportunities, including the perspectives of clinicians and researchers from the European College of Neuropsychopharmacology–Child and Adolescent Network, alongside those of experts by lived experience from national and international associations, via a survey involving 644 participants from 13 countries, and of regulators, through representation from the European Medicines Agency. We present and discuss the evidence base for medications currently used for mental disorders in children and adolescents, medications in the pipeline, opportunities in the development of novel medications, crucial priorities for the conduct of future clinical studies, challenges and opportunities in terms of the regulatory and legislative framework, and innovations in the way research is conducted, reported, and promoted.

Original language	English
Pages (from-to)	143-154
Number of pages	12
Journal	The Lancet Psychiatry
Volume	11
Issue number	2
DOIs	https://doi.org/10.1016/S2215-0366(23)00345-0
State	Published - Feb 2024
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2024 Elsevier Ltd

Funding

This paper is dedicated to the memory of our beloved colleague and friend Professor Alessandro Zuddas, who suddenly passed away in July, 2022. The authors are indebted to Valentina Mantua, of US Food and Drug Administration, Silver Spring, MD, USA, for invaluable suggestions on the manuscript. The authors acknowledge the contribution of the Psychiatry Expert Group and the Adolescent Expert Group of The Collaborative Network for European Clinical Trials for Children (conect4children; an action under the Innovative Medicines Initiative 2 Joint Understanding [https://www.imi.europa.eu]). The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its Committees or working parties.

Funders	Funder number
Psychiatry Expert Group
U.S. Food and Drug Administration
European Medicines Agency

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2215-0366(23)00345-0

Cite this

Cortese, S., Purper-Ouakil, D., Apter, A., Arango, C., Baeza, I., Banaschewski, T., Buitelaar, J., Castro-Fornieles, J., Coghill, D., Cohen, D., Correll, C. U., Grünblatt, E., Hoekstra, P. J., James, A., Jeppesen, P., Nagy, P., Pagsberg, A. K., Parellada, M., Persico, A. M., ... Moreno, C. (2024). Psychopharmacology in children and adolescents: unmet needs and opportunities. The Lancet Psychiatry, 11(2), 143-154. https://doi.org/10.1016/S2215-0366(23)00345-0

@article{1fdc47d2da324312ab78a36a584922eb,

title = "Psychopharmacology in children and adolescents: unmet needs and opportunities",

abstract = "Psychopharmacological treatment is an important component of the multimodal intervention approach to treating mental health conditions in children and adolescents. Currently, there are many unmet needs but also opportunities, alongside possible risks to consider, regarding the pharmacological treatment of mental health conditions in children and adolescents. In this Position Paper, we highlight and address these unmet needs and opportunities, including the perspectives of clinicians and researchers from the European College of Neuropsychopharmacology–Child and Adolescent Network, alongside those of experts by lived experience from national and international associations, via a survey involving 644 participants from 13 countries, and of regulators, through representation from the European Medicines Agency. We present and discuss the evidence base for medications currently used for mental disorders in children and adolescents, medications in the pipeline, opportunities in the development of novel medications, crucial priorities for the conduct of future clinical studies, challenges and opportunities in terms of the regulatory and legislative framework, and innovations in the way research is conducted, reported, and promoted.",

author = "Samuele Cortese and Diane Purper-Ouakil and Alan Apter and Celso Arango and Inmaculada Baeza and Tobias Banaschewski and Jan Buitelaar and Josefina Castro-Fornieles and David Coghill and David Cohen and Correll, {Christoph U.} and Edna Gr{\"u}nblatt and Hoekstra, {Pieter J.} and Anthony James and Pia Jeppesen and P{\'e}ter Nagy and Pagsberg, {Anne Katrine} and Mara Parellada and Persico, {Antonio M.} and Veit Roessner and Paramala Santosh and Emily Simonoff and Dejan Stevanovic and Argyris Stringaris and Benedetto Vitiello and Susanne Walitza and Abraham Weizman and Wong, {Ian C.K.} and Gil Zalsman and Alessandro Zuddas and Sara Carucci and Florence Butlen-Ducuing and Maria Tome and Myriam Bea and Christine Getin and Nina Hov{\'e}n and Asa Konradsson-Geuken and Daphne Lamirell and Nigel Olisa and {Nafria Escalera}, Begonya and Carmen Moreno",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = feb,

doi = "10.1016/S2215-0366(23)00345-0",

language = "אנגלית",

volume = "11",

pages = "143--154",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "Elsevier Ltd.",

number = "2",

}

Cortese, S, Purper-Ouakil, D, Apter, A, Arango, C, Baeza, I, Banaschewski, T, Buitelaar, J, Castro-Fornieles, J, Coghill, D, Cohen, D, Correll, CU, Grünblatt, E, Hoekstra, PJ, James, A, Jeppesen, P, Nagy, P, Pagsberg, AK, Parellada, M, Persico, AM, Roessner, V, Santosh, P, Simonoff, E, Stevanovic, D, Stringaris, A, Vitiello, B, Walitza, S, Weizman, A, Wong, ICK, Zalsman, G, Zuddas, A, Carucci, S, Butlen-Ducuing, F, Tome, M, Bea, M, Getin, C, Hovén, N, Konradsson-Geuken, A, Lamirell, D, Olisa, N, Nafria Escalera, B & Moreno, C 2024, 'Psychopharmacology in children and adolescents: unmet needs and opportunities', The Lancet Psychiatry, vol. 11, no. 2, pp. 143-154. https://doi.org/10.1016/S2215-0366(23)00345-0

TY - JOUR

T1 - Psychopharmacology in children and adolescents

T2 - unmet needs and opportunities

AU - Cortese, Samuele

AU - Purper-Ouakil, Diane

AU - Apter, Alan

AU - Arango, Celso

AU - Baeza, Inmaculada

AU - Banaschewski, Tobias

AU - Buitelaar, Jan

AU - Castro-Fornieles, Josefina

AU - Coghill, David

AU - Cohen, David

AU - Correll, Christoph U.

AU - Grünblatt, Edna

AU - Hoekstra, Pieter J.

AU - James, Anthony

AU - Jeppesen, Pia

AU - Nagy, Péter

AU - Pagsberg, Anne Katrine

AU - Parellada, Mara

AU - Persico, Antonio M.

AU - Roessner, Veit

AU - Santosh, Paramala

AU - Simonoff, Emily

AU - Stevanovic, Dejan

AU - Stringaris, Argyris

AU - Vitiello, Benedetto

AU - Walitza, Susanne

AU - Weizman, Abraham

AU - Wong, Ian C.K.

AU - Zalsman, Gil

AU - Zuddas, Alessandro

AU - Carucci, Sara

AU - Butlen-Ducuing, Florence

AU - Tome, Maria

AU - Bea, Myriam

AU - Getin, Christine

AU - Hovén, Nina

AU - Konradsson-Geuken, Asa

AU - Lamirell, Daphne

AU - Olisa, Nigel

AU - Nafria Escalera, Begonya

AU - Moreno, Carmen

PY - 2024/2

Y1 - 2024/2

N2 - Psychopharmacological treatment is an important component of the multimodal intervention approach to treating mental health conditions in children and adolescents. Currently, there are many unmet needs but also opportunities, alongside possible risks to consider, regarding the pharmacological treatment of mental health conditions in children and adolescents. In this Position Paper, we highlight and address these unmet needs and opportunities, including the perspectives of clinicians and researchers from the European College of Neuropsychopharmacology–Child and Adolescent Network, alongside those of experts by lived experience from national and international associations, via a survey involving 644 participants from 13 countries, and of regulators, through representation from the European Medicines Agency. We present and discuss the evidence base for medications currently used for mental disorders in children and adolescents, medications in the pipeline, opportunities in the development of novel medications, crucial priorities for the conduct of future clinical studies, challenges and opportunities in terms of the regulatory and legislative framework, and innovations in the way research is conducted, reported, and promoted.

AB - Psychopharmacological treatment is an important component of the multimodal intervention approach to treating mental health conditions in children and adolescents. Currently, there are many unmet needs but also opportunities, alongside possible risks to consider, regarding the pharmacological treatment of mental health conditions in children and adolescents. In this Position Paper, we highlight and address these unmet needs and opportunities, including the perspectives of clinicians and researchers from the European College of Neuropsychopharmacology–Child and Adolescent Network, alongside those of experts by lived experience from national and international associations, via a survey involving 644 participants from 13 countries, and of regulators, through representation from the European Medicines Agency. We present and discuss the evidence base for medications currently used for mental disorders in children and adolescents, medications in the pipeline, opportunities in the development of novel medications, crucial priorities for the conduct of future clinical studies, challenges and opportunities in terms of the regulatory and legislative framework, and innovations in the way research is conducted, reported, and promoted.

UR - http://www.scopus.com/inward/record.url?scp=85181653674&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(23)00345-0

DO - 10.1016/S2215-0366(23)00345-0

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 38071998

AN - SCOPUS:85181653674

SN - 2215-0366

VL - 11

SP - 143

EP - 154

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

IS - 2

ER -

Psychopharmacology in children and adolescents: unmet needs and opportunities

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this